Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Friday

Janux Therapeutics (NASDAQ:JANX) is expected to be issuing its quarterly earnings data before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $30.75 on Friday. The company has a market capitalization of $1.61 billion, a PE ratio of -26.28 and a beta of 3.16. The company has a 50 day simple moving average of $41.74 and a two-hundred day simple moving average of $47.55. Janux Therapeutics has a fifty-two week low of $29.63 and a fifty-two week high of $71.71.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Scotiabank cut their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Wedbush restated an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, BTIG Research increased their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $88.00.

Insiders Place Their Bets

In other Janux Therapeutics news, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer now directly owns 293,054 shares of the company’s stock, valued at $17,583,240. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,002 shares of company stock valued at $2,684,703 in the last three months. 29.40% of the stock is currently owned by insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.